Bimodal Release Two-In-One Clonazepam Matrix Lozenge Tablets for Managing Anxiety-Related Disorders: Formulation, Optimization and In Vivo Evaluation

Clonazepam (CLZ), an antipsychotic drug reported for its efficiency in managing anxiety-related disorders, is being marketed only as conventional tablets. Some patients have abstention to swallow the tablets; therefore, proposed study was aimed at developing a buccal lozenge tablet by direct compression of two types optimized granules. Conazepam’s water solubility first enhanced solid dispersion technique fast and better dissolution type 1 granules, while impact gelling polymers investigated on controlled-release 2 The formulae met acceptable pharmacopeial limits tablets’ evaluation. A differential scanning calorimetry revealed compatibility between used excipients. All gave burst release CLZ hour investigation, followed sustained over 24 h. formula that showed highest prolonged vitro (99.0 + 0.1%), following Higuchi diffusion model (R2 = 0.99), then selected further study. succeeded controlling induced stress rat with significant behavioral tests throughout experiment. results were confirmed pharmacokinetic increase Cmax, Tmax, AUC (1.5, 2, 3.9 folds), respectively, compared oral suspension. newly delivery system has proven efficacy reduced dosing frequency.